Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Synergistic innate and adaptive immune response to combination immunotherapy with anti-tumor antigen antibodies and extended serum half-life IL-2.

Zhu EF, Gai SA, Opel CF, Kwan BH, Surana R, Mihm MC, Kauke MJ, Moynihan KD, Angelini A, Williams RT, Stephan MT, Kim JS, Yaffe MB, Irvine DJ, Weiner LM, Dranoff G, Wittrup KD.

Cancer Cell. 2015 Apr 13;27(4):489-501. doi: 10.1016/j.ccell.2015.03.004.

2.

Synthesis and characterization of a novel chemically designed (Globo)3-DTPA-KLH antigen.

Hajmohammadi M, Siadat SD, Ghorbani M, Shafiee Ardestani M, Teimourian S, Asgari V, Ahangari Cohan R, Hajmohammadi M, Hajmohammadi A, Behzadi R, Rajab Nezhad S, Namvar Asl N.

Drug Des Devel Ther. 2014 Dec 22;9:217-39. doi: 10.2147/DDDT.S72530. eCollection 2015.

3.

Induction of leukocyte infiltration at metastatic site mediates the protective effect of NGcGM3-based vaccine.

Labrada M, Pablos I, Prete F, Hevia G, Clavell M, Benvenuti F, Fernández LE.

Hum Vaccin Immunother. 2014;10(8):2312-20. doi: 10.4161/hv.29161.

4.

Phase I trial of a bivalent gangliosides vaccine in combination with β-glucan for high-risk neuroblastoma in second or later remission.

Kushner BH, Cheung IY, Modak S, Kramer K, Ragupathi G, Cheung NK.

Clin Cancer Res. 2014 Mar 1;20(5):1375-82. doi: 10.1158/1078-0432.CCR-13-1012. Epub 2014 Feb 11.

5.

Accelerated tumor growth mediated by sublytic levels of antibody-induced complement activation is associated with activation of the PI3K/AKT survival pathway.

Wu X, Ragupathi G, Panageas K, Hong F, Livingston PO.

Clin Cancer Res. 2013 Sep 1;19(17):4728-39. doi: 10.1158/1078-0432.CCR-13-0088. Epub 2013 Jul 5.

6.

A targeted complement-dependent strategy to improve the outcome of mAb therapy, and characterization in a murine model of metastatic cancer.

Elvington M, Huang Y, Morgan BP, Qiao F, van Rooijen N, Atkinson C, Tomlinson S.

Blood. 2012 Jun 21;119(25):6043-51. doi: 10.1182/blood-2011-10-383232. Epub 2012 Mar 22.

7.

A monoclonal antibody to O-acetyl-GD2 ganglioside and not to GD2 shows potent anti-tumor activity without peripheral nervous system cross-reactivity.

Alvarez-Rueda N, Desselle A, Cochonneau D, Chaumette T, Clemenceau B, Leprieur S, Bougras G, Supiot S, Mussini JM, Barbet J, Saba J, Paris F, Aubry J, Birklé S.

PLoS One. 2011;6(9):e25220. doi: 10.1371/journal.pone.0025220. Epub 2011 Sep 22.

8.

Differential expression of FAK and Pyk2 in metastatic and non-metastatic EL4 lymphoma cell lines.

Zhang Z, Knoepp SM, Ku H, Sansbury HM, Xie Y, Chahal MS, Tomlinson S, Meier KE.

Clin Exp Metastasis. 2011 Aug;28(6):551-65. doi: 10.1007/s10585-011-9391-y. Epub 2011 May 1.

9.

Impact of minimal tumor burden on antibody response to vaccination.

Kim SK, Wu X, Ragupathi G, Gathuru J, Koide F, Cheung NK, Panageas K, Livingston PO.

Cancer Immunol Immunother. 2011 May;60(5):621-7. doi: 10.1007/s00262-011-0975-9. Epub 2011 Jan 26.

10.

Triptolide downregulates human GD3 synthase (hST8Sia I) gene expression in SK-MEL-2 human melanoma cells.

Kwon HY, Kim SJ, Kim CH, Son SW, Kim KS, Lee JH, Do SI, Lee YC.

Exp Mol Med. 2010 Dec 31;42(12):849-55.

11.

Construction and characterization of a novel fusion protein MG7-scFv/SEB against gastric cancer.

Tong Q, Liu K, Lu XM, Shu XG, Wang GB.

J Biomed Biotechnol. 2010;2010:121094. doi: 10.1155/2010/121094. Epub 2010 Mar 22.

12.

Immunotherapy for cancer: synthetic carbohydrate-based vaccines.

Buskas T, Thompson P, Boons GJ.

Chem Commun (Camb). 2009 Sep 28;(36):5335-49. doi: 10.1039/b908664c. Epub 2009 Jul 22. Review.

13.

Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice.

Wondimu A, Zhang T, Kieber-Emmons T, Gimotty P, Sproesser K, Somasundaram R, Ferrone S, Tsao CY, Herlyn D.

Cancer Immunol Immunother. 2008 Jul;57(7):1079-89.

15.

On the power of chemical synthesis: immunological evaluation of models for multiantigenic carbohydrate-based cancer vaccines.

Ragupathi G, Coltart DM, Williams LJ, Koide F, Kagan E, Allen J, Harris C, Glunz PW, Livingston PO, Danishefsky SJ.

Proc Natl Acad Sci U S A. 2002 Oct 15;99(21):13699-704. Epub 2002 Oct 1.

16.

Polyclonal antibodies from patients immunized with a globo H-keyhole limpet hemocyanin vaccine: isolation, quantification, and characterization of immune responses by using totally synthetic immobilized tumor antigens.

Wang ZG, Williams LJ, Zhang XF, Zatorski A, Kudryashov V, Ragupathi G, Spassova M, Bornmann W, Slovin SF, Scher HI, Livingston PO, Lloyd KO, Danishefsky SJ.

Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2719-24.

17.

Carbohydrate vaccines in cancer: immunogenicity of a fully synthetic globo H hexasaccharide conjugate in man.

Slovin SF, Ragupathi G, Adluri S, Ungers G, Terry K, Kim S, Spassova M, Bornmann WG, Fazzari M, Dantis L, Olkiewicz K, Lloyd KO, Livingston PO, Danishefsky SJ, Scher HI.

Proc Natl Acad Sci U S A. 1999 May 11;96(10):5710-5.

Supplemental Content

Support Center